Abstract:Abstract Purpose: We show that expression of GRP78, the master regulator of the endoplasmic reticulum (ER) stress response, leads to chemotherapy resistance in pancreatic ductal adenocarcinoma (PDAC) and utilize a small molecule inhibitor to block the activity of GRP78, increasing the efficacy of currently available therapies in vitro and in vivo. Background: Gemcitabine (GEM) is the standard chemotherapeutic agent for adjuvant therapy of PDAC and a commonly used agent in other treatment settings, including neoadjuvant treatment of borderline resectable PDAC and palliative treatment of metastatic PDAC. However, recurrent disease is observed in an alarming number of patients treated with GEM or GEM-based treatment regimens. A molecular-level understanding of the mechanisms that contribute to chemoresistance is essential for the development of more effective treatment strategies. ER chaperone proteins protect cells from apoptosis in response to cellular insults, including inflammation and pancreatitis. Elevated expression of chaperone proteins also causes the activation of many “pro-survival” pathways that promote cell survival and resistance to routinely utilized therapeutic regimens. We hypothesize that expression of ER chaperone protein GRP78, is responsible for innate and acquired resistant to GEM and that therapies targeting GRP78 by blocking its activity with the small molecule inhibitor, IT-139, could potentially improve patient response to GEM-based treatment regimens. Methods: We examined if GRP78 overexpression correlated with chemoresistance in PDAC through establishing a patient-derived orthotopic xenograft (PDX) model. Treating tumor-bearing mice with GEM continuously or releasing mice from GEM treatment after 3-4 weeks of exposure identified PDX lines that were either sensitive or resistant to GEM. Tumors from these cohorts were analyzed for GRP78 expression. To examine the role of GRP78 in chemoresistance in vitro, GRP78 expression was induced in GEM-sensitive cell lines prior to GEM treatment. Further, to investigate the effect of GRP78 loss on chemoresistance, siRNA knockdown of GRP78, followed by GEM treatment, was used in GEM-resistant cell lines. Finally, the efficacy of combination treatment with GEM and IT-139, a ruthenium-based anticancer drug and GRP78 inhibitor, was determined in vitro and in vivo. Results: Here, we report that PDX lines that result in GEM resistant PDAC have higher GRP78 expression than that of GEM sensitive PDX lines. In vitro, increased GRP78 induces chemoresistance in GEM-sensitive PDAC cell lines while knockdown of GRP78 reduces chemoresistance in GEM-resistant PDAC cell lines. Finally, we found that IT-139 can overcome GRP78 mediated chemoresistance. In vitro, IT-139 restores sensitivity to cytotoxic drugs in drug resistant PDAC cells and induces twice as much cell death in combination treatment compared with GEM alone. In vivo, a single weekly IT-139 treatment in combination with GEM caused a 35% increase in median survival and a 25% increase in overall survival compared to GEM alone. Conclusions: Collectively, our data show that GRP78 expression promotes chemoresistance in PDAC and therapeutic strategies blocking the activity of GRP78 increase the efficacy of currently available therapies. Citation Format: Jenifer B. Gifford, Wei Huang, Ann E. Zeleniak, Antreas Hindoyan, Hong Wu, Timothy R. Donahue, Reginald Hill.{Authors}. ER chaperone GRP78 increases chemoresistance in pancreatic ductal adenocarcinoma. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr B08.

Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer

Abstract 408: Novel growth hormone receptor antagonist with discrete PEGylations markedly improve response to therapy in human pancreatic and bile duct cancers in mice

Inhibition of P21 Activated Kinase Enhances Tumour Immune Response and Sensitizes Pancreatic Cancer to Gemcitabine

Abstract PR023: Targeting gemcitabine resistance in pancreatic cancer

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

Abstract A056: Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer

Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.

Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer

Hexosamine Pathway Inhibition Overcomes Pancreatic Cancer Resistance to Gemcitabine Through Unfolded Protein Response and EGFR-Akt Pathway Modulation

Targeting de novo lipogenesis improves gemcitabine efficacy in pancreatic ductal adenocarcinoma

Er Chaperone Grp78 Increases Chemoresistance In Pancreatic Ductal Adenocarcinoma

Abstract 4737: The combination of the BET inhibitor JQ1 and gemcitabine induces regressions in gemcitabine resistant patient-derived xenograft models of pancreatic cancer

Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model

Growth Hormone Upregulates Melanoma Drug Resistance and Migration via Melanoma-Derived Exosomes

Hedgehog Signaling Pathway Mediates Gemcitabine Intrinsic Chemoresistance in Pancreatic Cancer

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models.

pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model

Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition

GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression

Activation of GLP-1 Receptor Enhances the Chemosensitivity of Pancreatic Cancer Cells.